aTyr Pharma Beheer

Hoe is Sanjay Shukla's beloning veranderd ten opzichte van aTyr Pharma's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$64m
Jun 30 2024	n/a	n/a	-US$58m
Mar 31 2024	n/a	n/a	-US$54m
Dec 31 2023	US$1m	US$561k	-US$50m
Sep 30 2023	n/a	n/a	-US$43m
Jun 30 2023	n/a	n/a	-US$45m
Mar 31 2023	n/a	n/a	-US$45m
Dec 31 2022	US$2m	US$561k	-US$45m
Sep 30 2022	n/a	n/a	-US$46m
Jun 30 2022	n/a	n/a	-US$41m
Mar 31 2022	n/a	n/a	-US$39m
Dec 31 2021	US$2m	US$510k	-US$34m
Sep 30 2021	n/a	n/a	-US$30m
Jun 30 2021	n/a	n/a	-US$29m
Mar 31 2021	n/a	n/a	-US$25m
Dec 31 2020	US$1m	US$470k	-US$16m
Sep 30 2020	n/a	n/a	-US$17m
Jun 30 2020	n/a	n/a	-US$16m
Mar 31 2020	n/a	n/a	-US$16m
Dec 31 2019	US$664k	US$450k	-US$24m
Sep 30 2019	n/a	n/a	-US$24m
Jun 30 2019	n/a	n/a	-US$25m
Mar 31 2019	n/a	n/a	-US$30m
Dec 31 2018	US$1m	US$450k	-US$35m
Sep 30 2018	n/a	n/a	-US$40m
Jun 30 2018	n/a	n/a	-US$44m
Mar 31 2018	n/a	n/a	-US$45m
Dec 31 2017	US$2m	US$403k	-US$48m

Compensatie versus markt: De totale vergoeding ($USD 1.30M ) Sanjay } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 1.46M ).

Compensatie versus inkomsten: De vergoeding van Sanjay is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Sanjay Shukla (52 yo)

7yrs

Tenure

US$1,300,525

Compensatie

Dr. Sanjay S. Shukla, M.D. M.S. has been the Chief Executive Officer, President and Director at aTyr Pharma, Inc. since November 1, 2017. Dr. Shukla served as Chief Medical Officer at aTyr Pharma, Inc. fro...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Sanjay Shukla	President	7yrs	US$1.30m	0.16% $ 426.0k
Jill Broadfoot	Chief Financial Officer	6.3yrs	US$677.84k	0.025% $ 65.0k
Nancy E. Krueger	General Counsel & Corporate Secretary	10.1yrs	US$651.28k	0.027% $ 69.5k
Xiang-Lei Yang	Founder	no data	geen gegevens	geen gegevens
Jayant Aphale	Vice President of Technical Operations	less than a year	geen gegevens	geen gegevens
Ashlee Dunston	Director of Investor Relations & Corporate Communications	no data	geen gegevens	geen gegevens
Peter Villiger	Vice President of Corporate Development	4.8yrs	geen gegevens	geen gegevens
Danielle Campbell	VP of Human Resource	2.9yrs	geen gegevens	geen gegevens
Leslie Nangle	Vice President of Research	no data	geen gegevens	geen gegevens
Ying Buechler	Executive Director of Biologics Development & Manufacturing	no data	geen gegevens	geen gegevens
David King	Scientific Consultant	5.9yrs	US$717.31k	geen gegevens

5.9yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ATYR is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.9 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Sanjay Shukla	President	7yrs	US$1.30m	0.16% $ 426.0k
John Clarke	Independent Director	19.2yrs	US$120.84k	0.024% $ 61.8k
Paul Schimmel	Independent Director	19.2yrs	US$61.20k	1.31% $ 3.4m
Floyd Bloom	Member of Scientific Advisory Board	15.1yrs	geen gegevens	geen gegevens
Bruce Beutler	Member of Scientific Advisory Board	15.3yrs	geen gegevens	geen gegevens
Benjamin Cravatt	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Timothy Coughlin	Independent Chairman of the Board	7.6yrs	US$92.20k	0.067% $ 174.7k
Osamu Nureki	Member of Scientific Advisory Board	15.2yrs	geen gegevens	geen gegevens
Susan Ackerman	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Wing Wong	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Nancy Ip	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Jane Gross	Independent Director	5.3yrs	US$68.88k	0.0072% $ 18.7k

15.1yrs

Gemiddelde duur

67yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ATYR zijn ervaren en ervaren (gemiddelde ambtstermijn van 15.1 jaar).

aTyr Pharma Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Independent Director recently bought US$185k worth of stock

Independent Chairman of the Board recently bought US$88k worth of stock

aTyr Pharma, Inc., Annual General Meeting, May 22, 2024

Independent Director recently bought US$450k worth of stock

Insufficient new directors

Insufficient new directors

Recent updates

New minor risk - Financial position

New minor risk - Profitability

aTyr Pharma: Two 2025 Data Readouts Could Provide Inflection Point

New minor risk - Share price stability

Independent Director recently bought US$185k worth of stock

aTyr Pharma, Inc. Completes Enrollment in Global Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis

We Think aTyr Pharma (NASDAQ:ATYR) Needs To Drive Business Growth Carefully

Independent Chairman of the Board recently bought US$88k worth of stock

Price target increased by 8.8% to US$24.60

aTyr Pharma, Inc. Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis

Consensus revenue estimates decrease by 85%, EPS upgraded

aTyr Pharma, Inc., Annual General Meeting, May 22, 2024

Consensus revenue estimates fall by 70%

New minor risk - Profitability

New major risk - Revenue size

Forecast to breakeven in 2026

aTyr Pharma, Inc. to Report Q4, 2023 Results on Mar 14, 2024

aTyr Pharma, Inc. Announces Plans to Initiate an Individual Patient Expanded Access Program for Its Lead Therapeutic Candidate, Efzofitimod, for Patients with Pulmonary Sarcoidosis

We're Hopeful That aTyr Pharma (NASDAQ:LIFE) Will Use Its Cash Wisely

Consensus revenue estimates fall by 93%

Atyr Pharma, Inc. Announces Dosing of First Patient in Phase 2 Efzo-Connect™? Study of Efzofitimod in Patients with Ssc-Ild

Here's Why We're Not Too Worried About aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation

Atyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, Fvc and Patient Reported Outcomes

Consensus EPS estimates upgraded to US$0.90 loss

Price target increased by 17% to US$23.25

Consensus EPS estimates upgraded to US$1.03 loss

Independent Director recently bought US$450k worth of stock

Here's Why We're Watching aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation

Consensus revenue estimates fall by 25%

Price target increased by 8.9% to US$22.00

Consensus revenue estimates decrease by 25%

We're Keeping An Eye On aTyr Pharma's (NASDAQ:LIFE) Cash Burn Rate

Consensus forecasts updated

Price target decreased to US$21.20

Insufficient new directors

aTyr Pharma, Inc. Announces Publication of Positive Data from Phase 1B/2A Clinical Study of Efzofitimod for the Treatment of Pulmonary Sarcoidosis in the Journal Chest

aTyr Pharma, Inc. to Report Q3, 2022 Results on Nov 10, 2022

aTyr Pharma rises on U.S. patent for anti-neuropilin-2 monoclonal antibodies

aTyr Pharma, Inc. Announces Dosing of First Patient in Pivotal Phase 3 Efzo-Fit™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis

Consensus revenue estimates fall by 67%

aTyr Pharma stock rises on FDA fast track status for efzofitimod for lung disease

aTyr Pharma, Inc. Receives FDA Fast Track Designation for Efzofitimod (ATYR1923) for Treatment of Pulmonary Sarcoidosis

aTyr Pharma gains with FDA Fast Track status for lead asset

aTyr Pharma, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Price target decreased to US$17.33

Atyr Pharma, Inc. Announces Phase 3 Study Evaluating the Efficacy and Safety of Its Lead Therapeutic Candidate, efzofitimod

Consensus revenue estimates fall by 33%

We Think aTyr Pharma (NASDAQ:LIFE) Needs To Drive Business Growth Carefully

aTyr Pharma, Inc. to Report Q1, 2022 Results on May 09, 2022

Insufficient new directors

aTyr Pharma to Present Clinical Data for Efzofitimod (ATYR1923) at the American Thoracic Society 2022 International Conference

Full year 2021 earnings: EPS and revenues miss analyst expectations

Consensus forecasts updated

Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

aTyr Pharma, Inc. Advances Development of Lead Therapeutic Candidate ATYR1923 with Announcement of “efzofitimod” as Nonproprietary Name

aTyr Pharma: Successful Proof Of Concept In Pulmonary Sarcoidosis

Third quarter 2021 earnings released: US$0.42 loss per share (vs US$0.68 loss in 3Q 2020)

aTyr Stock Is Buoyant On Highly-Promising Lung Disease Data - Wait For Hype To Die Down And Buy

Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

aTyr Pharma, Inc. Announces Positive Data from Phase 1B/2A Clinical Trial Demonstrating Consistent Dose Response for Atyr1923 in Pulmonary Sarcoidosis

Price target increased to US$19.25

Consensus forecasts updated

Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

Independent Director recently bought US$199k worth of stock

Consensus forecasts updated

Price target increased to US$17.67

aTyr Pharma, Inc. (NASDAQ:LIFE) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Full year 2020 earnings released: US$1.77 loss per share (vs US$7.03 loss in FY 2019)

aTyr Pharma, Inc. to Report Q4, 2020 Results on Mar 23, 2021